Understanding Telix, page-1464

.Noteworthy developments in Prostate Cancer Detection and Treatment.

https://www.radiologytoday.net/archive/rt_AS24p22.shtml

Interesting the mention of improved hardware and AI allowing greater sensitivity, this may throw other greater sensitivity agents “advantage” out the window -

As an example of how these advancements can improve prostate cancer detection and patient throughput, Telix, in collaboration with BAMF, provided the first-in-human application of a PSMA scan with Illuccix, Telix’s molecular imaging agent to detect prostate cancer, on the uExplorer. “Micrometastic lesions were identified in a total body scan in several minutes,” Jessel says. “The uExplorer has >500,000 detectors, allowing greater sensitivity gain, detecting 40x more signal for the same radiation dose. The same injected dose can improve the signalto- noise ratio by more than six times, thereby allowing a less effective radiation dose. These advanced imaging scanners increase the dynamic range of the radiotracer, while current scanners collect <1% of the available signal.” Additionally, advanced scanners are coupled with the growing field of AI, which can enable faster and more accurate identification of complex patterns, as well as quantify and evaluate radiographic traits.